 | • レポートコード：MRC2203A789 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界の抗レトロウイルス薬市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤分類別（プロテアーゼ阻害剤、インテグラーゼ阻害剤、マルチクラス組み合わせ製品、ヌクレオシド逆転写酵素阻害剤（NRTI）、非ヌクレオシド逆転写酵素阻害剤（NNRTI））分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の抗レトロウイルス薬市場規模：薬剤分類別（プロテアーゼ阻害剤、インテグラーゼ阻害剤、マルチクラス組み合わせ製品、ヌクレオシド逆転写酵素阻害剤（NRTI）、非ヌクレオシド逆転写酵素阻害剤（NNRTI）） ・世界の抗レトロウイルス薬市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（AbbVie Inc.、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb Company、...） ・市場機会・将来の傾向 |
Antiretroviral are the drugs that treat HIV. Factors contributing to the growth of the market includes rising burden of HIV, increasing investment in R&D and increase in availability of novel drugs with better efficacy. According to the U.S. Department of Health & Human Services, there were approximately 37.9 million people worldwide that were living with HIV/AIDS. An estimated 1.7 million individuals worldwide became newly infected with HIV in 2018. Anti-retrovirals (ARVs) are the foundation of HIV/AIDS management, as currently there is no cure or vaccine available for HIV. In individuals with a non-resistant strain of HIV, the antiretroviral treatment can suppress the replication of HIV in about 80% of cases. This huge patient pool shows that the market for anti-retroviral drugs is expected to grow in the forecast period.
Key Market Trends
Multi-class Combination Products is Expected to Register a Significant Growth in the Forecast Years
Based on drug class, it is segmented into Integrase Inhibitors, Protease Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Others. The key factor contributing to the growth of the Multi-class Combination Products is the rising burden of HIV and new drug approval. According to WHO, around 770,000 people died from HIV in 2018. Many companies are focusing on developing breakthrough products for the treatment of antiretroviral drugs in order to maintain their competitive advantage and penetrate new regional markets. Additionally, the increase in funding for companies involved in the research related to anti-retroviral drugs is expected to boost the studied market.
North America holds the Largest Share in the Anti-retroviral Drugs Market
The Anti-retroviral Drugs market holds the largest share in the North America region. According to the U.S. Department of Health & Human Services, it is estimated that there are over 56,000 new cases of HIV in the United States each year and about 20 in 100 infected Americans do not know they have the virus. The growth is attributed to a high ART coverage rate and rising emphasis on prescribed branded drugs. In addition, the National Institutes of Health (NIH), United States, represents the largest public investment in HIV/AIDS research in the world, which is expected to fuel the market growth.
Competitive Landscape
The present demand of companies in the anti-retroviral segment is improving upon its research and development capabilities via collaboration, merger, and acquisition, as well as exploring new geographic regions. The global players in the anti-retroviral drugs market are – AbbVie Inc., Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Merck & Co, Inc., Mylan N.V., and ViiV Healthcare.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of HIV
4.2.2 Increasing Investment in R&D
4.2.3 Increase in Availability of Novel Drugs with Better Efficacy
4.3 Market Restraints
4.3.1 Side Effects of Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Protease Inhibitors
5.1.2 Integrase Inhibitors
5.1.3 Multi-class Combination Products
5.1.4 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
5.1.5 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.1.6 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Boehringer Ingelheim International GmbH
6.1.3 Bristol-Myers Squibb Company
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Gilead Sciences, Inc.
6.1.6 Merck & Co, Inc.
6.1.7 Mylan N.V.
6.1.8 ViiV Healthcare
7 MARKET OPPORTUNITIES AND FUTURE TRENDS